Southern Illinois University School Of Medicine Becomes Clinical Site For CEL-SCI (CVM)’s Global Phase 3 Immunotherapy Head And Neck Cancer Trial
4/28/2014 9:26:22 AM
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated another U.S. clinical site at Southern Illinois University School of Medicine’s Simmons Cancer Institute in Springfield, Illinois. The Illinois site, which has become part of the world’s largest Phase III trial for head and neck cancer with dozens of hospitals and clinical centers in 12 countries, has now officially joined the study. According to the National Cancer Institute, researchers estimated that about 52,000 men and women in the U.S. will be diagnosed with head and neck cancers annually.
Help employers find you! Check out all the jobs and post your resume.
comments powered by